Results 171 to 180 of about 45,512 (293)

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma. [PDF]

Cancer Res
Foth M, Kim W, O'Toole K, Murphy B, Justo-Garrido M, Boggaram S, Ghazi P, Brennan E, Wright MI, Shepherd T, Cortes-Sanchez E, Wang Y, Roth JA, Rees MG, Ronan MM, Jiang J, Wasko UN, Jiang A, Becker C, Deacon DC, Holmen SL, VanBrocklin MW, Hu-Lieskovan S, Kinsey CG, Russell JS, Hegde A, Garrido-Laguna I, Holderfield M, Singh M, McMahon M.   +29 more
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. [PDF]

Acta Oncol
Obinah MPB, Høgdall E, Poulsen TS, Dreisig K, Litman T, Johansen C, Bojesen SE, Hölmich LR.   +7 more
europepmc   +1 more source

Genetic Spectrum of Non‐PTPN11 Variants in Noonan Syndrome and Related RASopathies: Findings From a Russian Cohort

Clinical Genetics, Volume 110, Issue 5, Page 527-537, November 2026.
Noonan syndrome and related conditions are caused by variants in multiple genes. We analyzed 456 Russian patients using a 23‐gene panel and found disease‐causing variants in non‐PTPN11 genes in 85 cases. NF1, SOS1, BRAF, and SHOC2 explained half of these diagnoses.
Anna Orlova, Olga Shatokhina, Daria Guseva, Nina Demina, Aleksander Polyakov, Oхana Ryzkova   +5 more
wiley   +1 more source

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity. [PDF]

Blood Adv
Colgan JN, Peplinski JH, Wang YC, Kirkey DC, Wallace LK, Feng Y, Fan L, Connerty P, Ries RE, Lamble A, Huang BJ, Alonzo TA, Ma X, Tarlock K, Meshinchi S.   +14 more
europepmc   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

Journal of Cutaneous Pathology, Volume 53, Issue 11, Page 1042-1050, November 2026.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He, Shaymaa Hegazy, Phyu P. Aung, Priyadharsini Nagarajan, Fiorinda Muhaj, Adrienne N. Choksi, Ana M. Ciurea, Kelly C. Nelson, Doina Ivan, Carlos A. Torres‐ Cabala, Victor G. Prieto, Jonathan L. Curry   +11 more
wiley   +1 more source

Current Molecular-Targeted Therapies in Melanoma and Their Mechanism of Resistance. [PDF]

Cancers (Basel)
Bahari R, Nguyen M, Sohail N, Lopez S, Saravanaguru Vasanthi S, Amin J, Ramaswami D, Kapetaneas G, Karne R, Altayeh U, Rodgers KJ, Mehta AP, Puri N.   +12 more
europepmc   +1 more source

Protein palmitoylation in hematological malignancies: mechanistic links to lipid metabolic reprogramming and therapy resistance. [PDF]

Front Immunol
Zhao Q, Mei J, Qian S, Pu J, Li F.
europepmc   +1 more source

The Relevance of Curative‐Intent Metastasectomy in Colorectal Cancer Patients: Real‐World Insights From a Certified Comprehensive Cancer Center in Germany

International Journal of Cancer, Volume 159, Issue 8, Page 2025-2035, 15 October 2026.
Patients with metastatic colorectal cancer who are ineligible for upfront metastasectomy may still become candidates for secondary metastasectomy with curative intent following response to primary chemotherapy. However, most studies dichotomize metastatic colorectal cancer into resectable and unresectable disease.
Julian W. Holch, Jo‐Ann Eisenburger, Antony Weber, Iris Kammermeier‐Wehlau, Yannick Wiberg, Fabian Allmendinger, Kathrin Heinrich, Lena Weiss, C. Benedikt Westphalen, Victoria Krenmayr, Klara Dorman, Danmei Zhang, Theres Fey, Karin Berger‐Thürmel, Ulrich Wirth, Florian Kühn, Michael von Bergwelt‐Baildon, Jens Werner, Volker Heinemann   +18 more
wiley   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, Volume 20, Issue 10, Page 2410-2423, October 2026.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source